Gastrointestinal and Other Cancers Clinical Trials

Titlesort descending Intervention NCT ID Sponsor Status
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer Aspirin, Eflornithine, Laboratory Biomarker Analysis, Placebo, Telephone-Based Intervention NCT00983580 National Cancer Institute (NCI) Active, not recruiting
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma Aspirin, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration NCT02965703 National Cancer Institute (NCI) Recruiting
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful... Aspirin, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration NCT02521285 National Cancer Institute (NCI) Active, not recruiting
Bangladesh Vitamin E and Selenium Trial vitamin E, Selenium NCT00392561 University of Chicago Active, not recruiting
Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission Berberine Chloride, Laboratory Biomarker Analysis, Placebo NCT02365480 National Cancer Institute (NCI) Active, not recruiting
Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric... Curcumin, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment NCT02782949 National Cancer Institute (NCI) Recruiting
Defined Green Tea Catechin Extract in Preventing Liver Cancer in Patients With Cirrhosis Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration NCT03278925 National Cancer Institute (NCI) Recruiting
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection DNA Plasmid Encoding Interleukin-12 INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment NCT02772003 National Cancer Institute (NCI) Recruiting
Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers Laboratory Biomarker Analysis, Placebo, Questionnaire Administration, Dolcanatide NCT03300570 National Cancer Institute (NCI) Active, not recruiting
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment NCT02273362 National Cancer Institute (NCI) Recruiting

Pages